Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10591744 | Bioorganic & Medicinal Chemistry Letters | 2013 | 4 Pages |
Abstract
In an effort to understand the origin of blood-pressure lowering effects observed in recent clinical trials with 11β-HSD1 inhibitors, we examined a set of 11β-HSD1 inhibitors in a series of relevant in vitro and in vivo assays. Select 11β-HSD1 inhibitors reduced blood pressure in our preclinical models but most or all of the blood pressure lowering may be mediated by a 11β-HSD1 independent pathway.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
David R. Bauman, Alan Whitehead, Lisa C. Contino, Jisong Cui, Margarita Garcia-Calvo, Xin Gu, Nancy Kevin, Xiuying Ma, Lee-yuh Pai, Kashmira Shah, Xiaolan Shen, Sloan Stribling, Hratch J. Zokian, Joe Metzger, Diane E. Shevell, Sherman T. Waddell,